Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 39 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Keyword is Dyslipidemias [Clear All Filters]
Bone Health in Patients with Dyslipidemias: An Underestimated Aspect..
Int J Mol Sci. 23(3),
(2022). Dietary patterns and cardiovascular disease in Greek adults: The Hellenic National Nutrition and Health Survey (HNNHS)..
Nutr Metab Cardiovasc Dis. 30(2), 201-213.
(2020). Frequency and Quantity of Egg Intake Is Not Associated with Dyslipidemia: The Hellenic National Nutrition and Health Survey (HNNHS)..
Nutrients. 11(5),
(2019). Hypertension is the Prominent Risk Factor in Cataract Patients..
Medicina (Kaunas). 55(8),
(2019). Management of dyslipidaemias in the elderly population-A narrative review..
Maturitas. 124, 93-99.
(2019).
(2019). Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit?.
Maturitas. 108, 45-52.
(2018). Lipid management in patients with chronic kidney disease..
Nat Rev Nephrol. 14(12), 727-749.
(2018). The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia..
Curr Pharm Des. 23(10), 1495-1499.
(2017). Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action..
Indian Heart J. 68(5), 596-598.
(2016). Exploring the Management of Statin Intolerant Patients: 2016 and Beyond..
Curr Vasc Pharmacol. 14(6), 523-533.
(2016). Impaired metabolic profile is a predictor of capillary rarefaction in a population of hypertensive and normotensive individuals..
J Am Soc Hypertens. 10(8), 640-6.
(2016). Clinical controversies in lipid management..
Panminerva Med. 57(2), 65-70.
(2015). Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy..
Expert Rev Cardiovasc Ther. 13(9), 1059-66.
(2015). The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!.
Curr Med Res Opin. 30(9), 1701-5.
(2014). Are statins 'IDEAL' for non-alcoholic fatty liver disease?.
Curr Med Res Opin. 30(2), 229-31.
(2014). Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics..
Nat Rev Cardiol. 11(2), 72-4.
(2014). Statin therapy, fitness, and mortality risk in middle-aged hypertensive male veterans..
Am J Hypertens. 27(3), 422-30.
(2014). Statin-fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low..
Curr Med Res Opin. 30(1), 57-8.
(2014). Undertreatment of dyslipidemia: from the Arabian Gulf to the USA. Time to solve this problem!.
Curr Med Res Opin. 30(12), 2425-8.
(2014). Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property"..
Dig Liver Dis. 45(1), 82-3.
(2013). Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study..
Lancet. 381(9864), 394-9.
(2013). Statin and exercise prescription - Authors' reply..
Lancet. 381(9878), 1622-3.
(2013). Should raising high-density lipoprotein cholesterol be a matter of debate?.
J Cardiovasc Med (Hagerstown). 13(4), 254-9.
(2012).
(2011).